Invenio
Santa Clara, US · Founded 2012 · Delaware corporation · 17 employees on LinkedIn · 3 known investors
Invenio develops rapid on-site tissue imaging systems combined with AI to improve cancer patient care. The company serves pathologists and oncologists with real-time diagnostic tools for cancer detection.
Founders & leadership
Invenio was founded in 2012 by Jay Trautman, Chris Freudiger, Christian Freudiger, and Xiaoliang Xie.
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$7.5M disclosed across 3 rounds · 2015–2021
▶$3MraisedFeb 2021 · 9 investors · Other TechnologyRule 506(b)
- Michael Ming-Yih WuDirector
- Douglas CrawfordDirector
- Christian FreudigerDirector
- Jay TrautmanExecutive Officer, Director
- Offering amount
- $3.3M
- Amount sold
- $3M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedJan 2019 · 9 investors · Other TechnologyRule 506(b)
- DANIEL ORRINGERDirector
- DOUGLAS CRAWFORDDirector
- JAY TRAUTMANExecutive Officer, Director
- XIAOLIANG XIEDirector
- CHRISTIAN FREUDIGERDirector
- Offering amount
- $3.7M
- Amount sold
- $3.5M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedDec 2015 · 3 investors · Other TechnologyRule 506(b)
- Christian FreudigerDirector
- Jay TrautmanExecutive Officer, Director
- Doug CrawfordDirector
- Xiaoliang XieDirector
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Invenio for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 7 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $945.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $224.3K |
| National Science Foundation | Phase II | 2013 | $732.6K |
| National Science Foundation | Phase I | 2013 | $150K |
| National Science Foundation | Phase I | 2012 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Invenio do?
- Invenio develops rapid on-site tissue imaging systems combined with AI to improve cancer patient care. The company serves pathologists and oncologists with real-time diagnostic tools for cancer detection.
- Who founded Invenio?
- Invenio was founded by Jay Trautman, Chris Freudiger, Christian Freudiger, Xiaoliang Xie in 2012.
- Who are Invenio's investors?
- Invenio's investors include Berkeley Catalyst, Mission Bay Capital, Mission Biocapital.
- How much funding has Invenio raised?
- Invenio has disclosed $7.5M raised across 3 rounds.
- Where is Invenio headquartered?
- Invenio is headquartered in Santa Clara, US.